Rafael Holdings, Inc.
Known title: 10% OwnerCIK: 0001713863
Rafael Holdings, Inc.'s purchase track record
Rafael Holdings, Inc. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/1/2023 | RFL | $5.00M | -12.3% | -10.3% | +7.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RFL | ▼ Sell | Other | 3,968,254 | $2.5M | 12/23/2024 | View on chart |
| RFL | ▼ Sell | Other | 2,514,970 | $1.8M | 10/20/2023 | View on chart |
| RFL | ▲ Buy | Open Market | 4,000,000 | $5.0M | 8/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Rafael Holdings stock drops after Phase 3 trial misses goal
Rafael Holdings shares fell sharply after the company reported that its Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance in treating Niemann-Pick Disease Type C. The trial involved 94 patients, and the lack of efficacy results led to a significant decline in the stock price. This outcome highlights the risks associated with late-stage clinical trials for rare disease treatments.
Rafael Holdings stock drops after Phase 3 trial misses goal. Rafael Holdings shares fell sharply after the company reported that its Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance in treating Niemann-Pick Disease Type C. The trial involved 94 patients, and the lack of efficacy results led to a significant decline in the stock price. This outcome highlights the risks associated with late-stage clinical trials for rare disease treatments.